110 related articles for article (PubMed ID: 35588228)
1. Decreased EMILIN2 correlates to metabolism phenotype and poor prognosis of ovarian cancer.
Tang X; Li F
J Biochem; 2022 Jul; 172(2):89-97. PubMed ID: 35588228
[TBL] [Abstract][Full Text] [Related]
2. Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.
Zhou Y; Zheng X; Lu J; Chen W; Li X; Zhao L
Cell Physiol Biochem; 2018; 45(6):2548-2559. PubMed ID: 29558748
[TBL] [Abstract][Full Text] [Related]
3. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.
Wang LC; Cui WY; Zhang Z; Tan ZL; Lv QL; Chen SH; Shen XL
Brain Res Bull; 2021 Oct; 175():26-36. PubMed ID: 34280481
[TBL] [Abstract][Full Text] [Related]
4. miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.
Lu J; Wang L; Chen W; Wang Y; Zhen S; Chen H; Cheng J; Zhou Y; Li X; Zhao L
Arch Biochem Biophys; 2019 Jan; 661():1-9. PubMed ID: 30365936
[TBL] [Abstract][Full Text] [Related]
5. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.
Torng PL; Lin CW; Chan MW; Yang HW; Huang SC; Lin CT
Mol Cancer; 2009 Dec; 8():120. PubMed ID: 20003326
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
8. The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
Alvarez Secord A; Darcy KM; Hutson A; Huang Z; Lee PS; Jewell EL; Havrilesky LJ; Markman M; Muggia F; Murphy SK
Gynecol Oncol; 2011 Nov; 123(2):314-9. PubMed ID: 21903246
[TBL] [Abstract][Full Text] [Related]
9. Methylation in the p53 promoter in epithelial ovarian cancer.
Chmelarova M; Krepinska E; Spacek J; Laco J; Beranek M; Palicka V
Clin Transl Oncol; 2013 Feb; 15(2):160-3. PubMed ID: 22855178
[TBL] [Abstract][Full Text] [Related]
10. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration.
Marastoni S; Andreuzzi E; Paulitti A; Colladel R; Pellicani R; Todaro F; Schiavinato A; Bonaldo P; Colombatti A; Mongiat M
J Pathol; 2014 Mar; 232(4):391-404. PubMed ID: 24374807
[TBL] [Abstract][Full Text] [Related]
11. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
12. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside 20(S)-Rg3 Prevents PKM2-Targeting miR-324-5p from H19 Sponging to Antagonize the Warburg Effect in Ovarian Cancer Cells.
Zheng X; Zhou Y; Chen W; Chen L; Lu J; He F; Li X; Zhao L
Cell Physiol Biochem; 2018; 51(3):1340-1353. PubMed ID: 30481782
[TBL] [Abstract][Full Text] [Related]
14. Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis.
Andreuzzi E; Fejza A; Capuano A; Poletto E; Pivetta E; Doliana R; Pellicani R; Favero A; Maiero S; Fornasarig M; Cannizzaro R; Iozzo RV; Spessotto P; Mongiat M
Matrix Biol Plus; 2020 May; 6-7():100029. PubMed ID: 33543026
[TBL] [Abstract][Full Text] [Related]
15. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
Barton CA; Gloss BS; Qu W; Statham AL; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
Br J Cancer; 2010 Jan; 102(1):87-96. PubMed ID: 19935792
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Sep; 30(37):3930-42. PubMed ID: 21478913
[TBL] [Abstract][Full Text] [Related]
18. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
19. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
20. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
